Latest Precision Medicine News

Page 1 of 5
PYC Therapeutics has successfully closed a $537 million institutional placement and entitlement offer, positioning the company to raise at least $600 million to advance its RNA-based therapies targeting genetic diseases.
Ada Torres
Ada Torres
4 Feb 2026
PYC Therapeutics has launched a substantial $653 million equity raise to fund clinical trials for four promising drug candidates targeting genetic diseases. This capital injection aims to advance the company’s pipeline through critical human efficacy milestones.
Ada Torres
Ada Torres
2 Feb 2026
Cyclopharm has launched a pioneering clinical study combining its Technegas imaging with AI analysis to explore a novel treatment for severe COPD, potentially expanding care options for millions.
Ada Torres
Ada Torres
29 Jan 2026
Argenica Therapeutics has unveiled compelling AI-driven results confirming ARG-007’s significant benefits in severe acute ischemic stroke patients, setting the stage for a precision-focused Phase 2b trial.
Ada Torres
Ada Torres
28 Jan 2026
A small-cap healthcare rally had a clear centre: distribution deals, US regulatory steps, and big cheques. Osteopore, Echo IQ and Anteris led the week, while a handful of names slipped despite solid operational updates.
Logan Eniac
Logan Eniac
25 Jan 2026
A takeover offer lit up small caps, while one high-growth software name slid hard despite strong sector news. Resources dominated the winners list, but investors still punished dilution and discounted fundraisings.
Logan Eniac
Logan Eniac
24 Jan 2026
Rhythm Biosciences has begun commercialising its blood-based colorectal cancer test, ColoSTAT®, following key accreditations and validation. The company also secured a strategic partnership with NHS England and expanded its geneType™ platform globally.
Ada Torres
Ada Torres
23 Jan 2026
The Garvan Institute has won a $3 million MRFF grant to conduct pivotal pancreatic cancer studies, including one evaluating Syntara’s amsulostat combined with chemotherapy. Recruitment is slated to begin mid-2026 across major NSW cancer centres.
Ada Torres
Ada Torres
21 Jan 2026
Telix Pharmaceuticals has met its upgraded FY 2025 revenue guidance with US$804 million, driven by strong growth in its Precision Medicine segment and the successful US launch of Gozellix. The company also advanced multiple clinical trials and announced a strategic collaboration with Varian to combine radiopharmaceuticals with radiation therapy.
Ada Torres
Ada Torres
20 Jan 2026
Telix Pharmaceuticals has achieved a key milestone with China’s NMPA accepting its New Drug Application for Illuccix, a prostate cancer imaging agent backed by strong Phase 3 data. This paves the way for Telix to enter a rapidly growing Chinese market alongside its global approvals.
Ada Torres
Ada Torres
20 Jan 2026
Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.
Ada Torres
Ada Torres
14 Jan 2026
PYC Therapeutics reports positive safety outcomes from the initial phase of its clinical trial for PYC-003, a promising treatment for Polycystic Kidney Disease. The drug was well tolerated in healthy volunteers, paving the way for patient dosing and further trials.
Ada Torres
Ada Torres
19 Dec 2025